Similar articles

• [TNF targetting therapy for rheumatoid arthritis].

  Takeuchi T. Takeuchi T. Nihon Naika Gakkai Zasshi. 2006 Sep 10;95(9):1787-94. doi: 10.2169/naika.95.1787. Nihon Naika Gakkai Zasshi. 2006. PMID: 17037316 Review. Japanese. No abstract available.
• Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.

  Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Østergaard M; All Departments of Rheumatology in Denmark. Hetland ML, et al. Arthritis Rheum. 2010 Jan;62(1):22-32. doi: 10.1002/art.27227. Arthritis Rheum. 2010. PMID: 20039405
• Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study.

  Fleischmann R, Goldman JA, Leirisalo-Repo M, Zanetakis E, El-Kadi H, Kellner H, Bolce R, DeHoratius R, Wang J, Decktor D. Fleischmann R, et al. Curr Med Res Opin. 2014 Nov;30(11):2139-49. doi: 10.1185/03007995.2014.942416. Epub 2014 Jul 30. Curr Med Res Opin. 2014. PMID: 25050591 Clinical Trial.
• Questions and answers in 2008 about biologics in rheumatoid arthritis.

  Weinblatt ME. Weinblatt ME. J Rheumatol. 2008 Sep;35(9):1878-81. J Rheumatol. 2008. PMID: 18785296 No abstract available.
• Rheumatoid arthritis: more aggressive approach improves outlook.

  Weinblatt ME. Weinblatt ME. Cleve Clin J Med. 2004 May;71(5):409-13. doi: 10.3949/ccjm.71.5.409. Cleve Clin J Med. 2004. PMID: 15195775 Review.